Oregon Public Employees Retirement Fund Invests $2.01 Million in Elanco Animal Health Incorporated $ELAN

Oregon Public Employees Retirement Fund bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 100,000 shares of the company’s stock, valued at approximately $2,014,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ELAN. Primecap Management Co. CA boosted its stake in Elanco Animal Health by 3.1% during the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock worth $739,230,000 after buying an additional 1,543,279 shares during the period. Brandes Investment Partners LP raised its stake in shares of Elanco Animal Health by 11.3% in the second quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock valued at $115,673,000 after acquiring an additional 820,901 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Elanco Animal Health by 322.0% during the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock worth $46,192,000 after purchasing an additional 2,468,122 shares during the period. Finally, Holocene Advisors LP boosted its stake in shares of Elanco Animal Health by 29.1% during the 2nd quarter. Holocene Advisors LP now owns 2,886,294 shares of the company’s stock worth $41,216,000 after purchasing an additional 649,820 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ELAN shares. Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Wednesday, November 19th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday. Morgan Stanley boosted their price objective on Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, December 18th. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. Finally, Stifel Nicolaus lifted their target price on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health has an average rating of “Moderate Buy” and an average price target of $23.78.

Elanco Animal Health Trading Up 2.3%

ELAN opened at $24.42 on Wednesday. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. The stock’s fifty day moving average is $22.33 and its two-hundred day moving average is $19.50. The company has a market capitalization of $12.13 billion, a P/E ratio of 407.03, a PEG ratio of 3.32 and a beta of 1.87. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $24.47.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, December 12th. The stock was acquired at an average price of $21.30 per share, for a total transaction of $213,000.00. Following the acquisition, the director owned 131,773 shares in the company, valued at $2,806,764.90. This trade represents a 8.21% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rajeev A. Modi purchased 4,500 shares of the stock in a transaction dated Thursday, December 11th. The stock was acquired at an average cost of $21.33 per share, with a total value of $95,985.00. Following the transaction, the insider directly owned 123,082 shares in the company, valued at approximately $2,625,339.06. This trade represents a 3.79% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 43,450 shares of company stock worth $937,883. Company insiders own 0.89% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.